首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies
【2h】

Antigen Design for Successful Isolation of Highly Challenging Therapeutic Anti-GPCR Antibodies

机译:抗原设计成功分离高度挑战性抗GPCR抗体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

G-protein-coupled receptors (GPCR) transmit extracellular signals into cells to regulate a variety of cellular functions and are closely related to the homeostasis of the human body and the progression of various types of diseases. Great attention has been paid to GPCRs as excellent drug targets, and there are many commercially available small-molecule chemical drugs against GPCRs. Despite this, the development of therapeutic anti-GPCR antibodies has been delayed and is challenging due to the difficulty in preparing active forms of GPCR antigens, resulting from their low cellular expression and complex structures. Here, we focus on anti-GPCR antibodies that have been approved or are subject to clinical trials and present various technologies to prepare active GPCR antigens that enable the isolation of therapeutic antibodies to proceed toward clinical validation.
机译:G蛋白偶联受体(GPCR)将细胞外信号传递到细胞中以调节各种细胞功能,并且与人体的稳态和各种类型疾病的进展密切相关。为GPCR作为优秀的药物目标支付了很大的关注,并且有许多用于GPCR的商业上可获得的小分子化学药物。尽管如此,治疗性抗GPCR抗体的发展已经延迟,并且由于难以制备GPCR抗原的活性形式,因此是由它们的低细胞表达和复杂结构产生的挑战。这里,我们专注于已被批准或受到临床试验的抗GPCR抗体,并呈现各种技术,以制备活性GPCR抗原,使治疗性抗体能够进行临床验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号